首页> 外文期刊>British Journal of Clinical Pharmacology >A placebo-controlled study examining the effect of allopurinol on heart rate variability and dysrhythmia counts in chronic heart failure.
【24h】

A placebo-controlled study examining the effect of allopurinol on heart rate variability and dysrhythmia counts in chronic heart failure.

机译:一项安慰剂对照研究,研究了别嘌呤醇对慢性心力衰竭患者心率变异性和心律失常计数的影响。

获取原文
获取原文并翻译 | 示例
       

摘要

AIMS: Allopurinol improves endothelial function in chronic heart failure by reducing oxidative stress. We wished to explore if such an effect would attenuate autonomic dysfunction in CHF in line with many other effective therapies in CHF. METHODS: We performed a prospective, randomized, double-blind cross-over study in 16 patients with NYHA Class II-IV chronic heart failure (mean age 67 +/- 10 years, 13 male, comparing allopurinol (2 months) at a daily dose of 300 mg (if creatinine < 150 micromol l-1) or 100 mg (if creatinine > 150 micromol l-1) with matched placebo. Mean heart rate and dysrhythmia counts were recorded from 24 h Holter tapes at monthly intervals for 6 months. We assessed autonomic function using standard time domain heart rate variability parameters (HRV): SDNN, SDANN, SDNN index, rMSSD and TI. RESULTS: Allopurinol had no significant effect on heart rate variability compared with placebo; the results are expressed as a difference in means +/- s.d. with 95% confidence interval (CI) between allopurinol and placebo: SDNN mean = 6.5 +/- 4.8 ms, P = 0.18 and 95% CI (-3.7, 17); TI mean = -2.1 +/- 1.4, P = 0.16 and 95% CI (-5.2, 0.8); SDANN mean = -2.8 +/- 7 ms, P = 0.68 and 95% CI (-18, 12); SDNNi mean = 2 +/- 6.6, P = 0.7 and 95% CI (-12, 16); RMSSD mean = -0.9 +/- 2, P = 0.68 and 95% CI (-5.6, 3.7). For mean heart rate the corresponding results were 0.9 +/- 1.4, P = 0.5 and 95% CI (-2, 3.8). Log 24 h ventricular ectopic counts (VEC) were 0.032 +/- 0.37, P = 0.7 and 95% CI (-0.1, 0.2). Patient compliance with study medication was good since allopurinol showed its expected effect of reducing plasma uric acid (P < 0.001). CONCLUSIONS: Allopurinol at doses, which are known to reduce oxidative stress appear to have no significant effect on resting autonomic tone, as indicated by time domain heart rate variability or on dysrhythmia count in stable heart failure patients.
机译:目的:别嘌呤醇通过减少氧化应激改善慢性心力衰竭的内皮功能。我们希望探讨这种作用是否会与CHF的许多其他有效疗法相一致地减轻CHF的自主神经功能障碍。方法:我们对16例NYHA II-IV级慢性心力衰竭(平均年龄67 +/- 10岁,13例男性)的前瞻性,随机,双盲交叉研究进行了比较,每天比较别嘌醇(2个月)剂量为300毫克(如果肌酐<150微摩尔l-1)或100毫克(如果肌酐> 150微摩尔l-1)和匹配的安慰剂,平均心率和心律不齐计数记录于24小时的Holter磁带中,间隔6个月我们使用标准时域心率变异性参数(HRV)评估了自主神经功能:SDNN,SDANN,SDNN指数,rMSSD和TI结果:与安慰剂相比,别嘌呤醇对心率变异性无显着影响;结果表示为差异均值+/- SD与别嘌醇和安慰剂之间的置信区间(CI)为95%:SDNN平均值= 6.5 +/- 4.8毫秒,P = 0.18和95%CI(-3.7,17); TI平均值= -2.1 + / -1.4,P = 0.16和95%CI(-5.2,0.8); SDANN平均值= -2.8 +/- 7 ms,P = 0.68和95%CI(-18,12); SDNNi平均值= 2 + / -6.6,P = 0.7和95%CI(-12,16); RMSSD平均值= -0.9 +/- 2,P = 0.68和95%CI(-5.6,3.7)。对于平均心率,相应的结果为0.9 +/- 1.4,P = 0.5和95%CI(-2,3.8)。 Log 24 h心室异位计数(VEC)为0.032 +/- 0.37,P = 0.7和95%CI(-0.1,0.2)。患者对研究药物的依从性良好,因为别嘌醇显示出其降低血浆尿酸的预期效果(P <0.001)。结论:稳定的心力衰竭患者,时空心率变异性或心律失常计数表明,已知能降低氧化应激的别嘌呤醇似乎对静息自主神经无明显影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号